{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=15", "query": { "intervention": "Placebo (treatment C)", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 988, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T15:36:22.015Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04770389", "title": "Randomized Study of Obicetrapib in Combination With Ezetimibe", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemias", "High Cholesterol", "Hypercholesterolemia" ], "interventions": [ { "name": "Obicetrapib 5mg", "type": "DRUG" }, { "name": "Ezetimibe 10mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 112, "start_date": "2021-02-23", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 3, "location_summary": "Lincoln, California • Evanston, Illinois • Houston, Texas", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04770389" }, { "nct_id": "NCT07437105", "title": "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-272", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tezacaftor", "type": "DRUG" }, { "name": "Deutivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 160, "start_date": "2026-02-25", "completion_date": "2027-06-26", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07437105" }, { "nct_id": "NCT04394351", "title": "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "11 Years", "sex": "ALL", "summary": "1 Year to 11 Years" }, "enrollment_count": 102, "start_date": "2020-09-01", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04394351" }, { "nct_id": "NCT07619131", "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Laroprovstat", "type": "DRUG" }, { "name": "Rosuvastatin 1", "type": "DRUG" }, { "name": "Rosuvastatin 2", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Placebo to match rosuvastatin", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 2", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat/Rosuvastatin 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 600, "start_date": "2026-08-12", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 77, "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619131" }, { "nct_id": "NCT03703102", "title": "Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "KHK4083", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2018-10-22", "completion_date": "2020-11-12", "has_results": true, "last_update_posted_date": "2024-04-26", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 13, "location_summary": "Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703102" }, { "nct_id": "NCT01972529", "title": "Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Thrombocytopenia Associated With Liver Disease" ], "interventions": [ { "name": "avatrombopag (lower baseline platelet count)", "type": "DRUG" }, { "name": "placebo (lower baseline platelet count)", "type": "DRUG" }, { "name": "avatrombopag (higher baseline platelet count)", "type": "DRUG" }, { "name": "placebo (higher baseline platelet count)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2014-02", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 21, "location_summary": "Lancaster, California • Long Beach, California • Los Angeles, California + 18 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972529" }, { "nct_id": "NCT01272830", "title": "Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Edematous", "Synovitis", "Foreign Body Reaction", "Osteolysis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Apatone®B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IC-MedTech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 57, "start_date": "2010-10", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 1, "location_summary": "Akron, Ohio", "locations": [ { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272830" }, { "nct_id": "NCT00539981", "title": "Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "FluBlok®", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 4648, "start_date": "2007-09-15", "completion_date": "2008-05-28", "has_results": true, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 24, "location_summary": "Beverly Hills, California • Sacramento, California • San Francisco, California + 20 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00539981" }, { "nct_id": "NCT02138253", "title": "A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Fibrosis", "Hepatic Fibrosis", "Liver Cirrhosis", "Hepatic Cirrhosis" ], "interventions": [ { "name": "IDN-6556", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conatus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2014-05", "completion_date": "2018-03-09", "has_results": true, "last_update_posted_date": "2019-12-11", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 35, "location_summary": "Coronado, California • La Jolla, California • Loma Linda, California + 24 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02138253" }, { "nct_id": "NCT02918266", "title": "TAK-071 Scopolamine-Induced Cognitive Impairment Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Scopolamine", "type": "DRUG" }, { "name": "TAK-071", "type": "DRUG" }, { "name": "Donepezil", "type": "DRUG" }, { "name": "Scopolamine Placebo", "type": "DRUG" }, { "name": "TAK-071 Placebo", "type": "DRUG" }, { "name": "Donepezil Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 18, "start_date": "2016-11-21", "completion_date": "2017-08-08", "has_results": true, "last_update_posted_date": "2019-06-14", "last_synced_at": "2026-10-15T15:36:22.015Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02918266" } ] }